Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19302297 | 0.87 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL1242591 | 0.86 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL4901784 | 0.84 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL22031408 | 0.83 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL9307391 | 0.81 | — | — | |
| SCHEMBL968263 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL10775962 | 0.78 | — | — | |
| SCHEMBL30978337 | 0.78 | ALDH1A1 (0.39) | ALDH1A1 | |
| Bromide SCHEMBL32665865 | 0.78 | ALDH1A1 (0.39) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5167435 | 0.78 | ALDH1A1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125031-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | Novosom AG (DE) | 2009-12-02 | — | — | EP | claimed |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | CEQUENT PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | claimed |
| EP-1938843-A1 | Lipids and lipid assemblies comrising transfection enhancer elements | Novosom AG (DE) | 2008-07-02 | — | — | EP | claimed |
| WO-2008074487-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | NOVOSOM AG (DE) | 2008-06-26 | — | — | WO | claimed |
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. | 2008-06-19 | — | — | US | claimed |
| US-7189705-B2 | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2007-03-13 | — | — | US | claimed |
| US-6852334-B1 | Cationic peg-lipids and methods of use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2005-02-08 | — | — | US | claimed |
| US-20040241855-A1 | Cationic peg-lipids and methods of use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2004-12-02 | — | — | US | claimed |
| EP-1355670-A2 | ENHANCED STABILISED PLASMID-LIPID PARTICLE-MEDIATED TRANSFECTION USING ENDOSOMAL MEMBRANE DESTABILISERS | University of British Columbia (CA) | 2003-10-29 | — | — | EP | claimed |
| EP-1328254-A2 | LIPID FORMULATIONS FOR TARGET DELIVERY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2003-07-23 | — | — | EP | claimed |
| US-20020072121-A1 | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2002-06-13 | — | — | US | claimed |
| WO-2002034236-A2 | LIPID FORMULATIONS FOR TARGET DELIVERY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-05-02 | — | — | WO | claimed |
| EP-1173600-A2 | CATIONIC PEG-LIPIDS AND METHODS OF USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-01-23 | — | — | EP | claimed |
| WO-2001080900-A2 | ENHANCED STABILISED PLASMID-LIPID PARTICLE-MEDIATED TRANSFECTION USING ENDOSOMAL MEMBRANE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-01 | — | — | WO | claimed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-20240229034-A1 | LIPID NANOPARTICLES AND METHODS OF USE | CITY OF HOPE | 2024-07-11 | — | — | US | disclosed |
| WO-2024141105-A1 | LIPID COMPOUND FOR GENE DELIVERY AND LIPID NANOPARTICLE COMPRISING SAME | 南京星辰智曜生物医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2000062813-A2 | CATIONIC PEG-LIPIDS AND METHODS OF USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2000-10-26 | — | — | WO | disclosed |
| EP-1041976-A1 | POLYAMIDE OLIGOMERS | Inex Pharmaceuticals Corp. (CA) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033493-A1 | POLYAMIDE OLIGOMERS | INEX PHARMACEUTICALS CORPORATION (CA) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | HNRNPH3, SREBF2, PHOSPHO1 | ALDH1A1 4867/4885 |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | SREBF1, SREBF2, ELOVL1 | ALDH1A1 3614/4885 |
| US-20020072121-A1 | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers | PLTP, SCAMP2, SCAMP3 | ALDH1A1 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.